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ABSTRACT
Introduction: Saxagliptin, sitagliptin, and
vildagliptin are dipeptidyl peptidase-4 (DPP-4)
inhibitors widely approved for use in patients
with type 2 diabetes. Using a crossover design,
the present study compared trough levels of
DPP-4 inhibition provided by these agents in a
single cohort of patients with type 2 diabetes.
Methods: This was a randomized, placebo-
controlled, open-label, five-period crossover
study. Eligible patients were 18–65 years of
age, either treatment-naı¨ve or off prior
antihyperglycemic agent therapy for at least 6
or 12 weeks (depending on the prior therapy),
and had glycated hemoglobin (HbA1C) C6.5%
and B10.0%. In separate study periods, patients
received 5 mg saxagliptin q.d. (saxa-5), 100 mg
sitagliptin q.d. (sita-100), 50 mg vildagliptin q.d.
(vilda-50-q.d.), 50 mg vildagliptin b.i.d. (vilda-
50-b.i.d.), or placebo for 5 days. The primary
endpoint was trough %DPP-4 inhibition,
derived by comparing DPP-4 activity 24 h after
the Day-5 morning dose with predose activity in
the same period and analyzed using a linear
mixed-effects model with fixed-effects terms for
treatment and period.
Results: Mean (range) baseline HbA1C was 7.4%
(6.4–9.0%; N = 22). Least-squares (LS) mean
trough %DPP-4 inhibition was 73.5%, 91.7%,
28.9%, 90.6%, and 3.5% after saxa-5, sita-100,
vilda-50-q.d., vilda-50-b.i.d., and placebo,
respectively. In patients treated with sita-100,
the LS-mean difference in trough %DPP-4
inhibition was 18.2% greater than with saxa-5
(p\0.001), 62.9% greater than with vilda-50-
q.d. (p\0.001), 1.1% greater than with vilda-
50-b.i.d. (p = 0.128), and 87.8% greater than
with placebo (p\0.001). Mean %DPP-4
inhibition was nearly maximal at 12 h
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postdose regardless of active treatment. Thus,
these between-group comparisons at trough
primarily reflected differences in duration of
action. Adverse events reported during the
study were transient and mild or moderate in
intensity.
Conclusion: Once daily treatment with
sitagliptin provided trough DPP-4 inhibition
significantly greater than saxagliptin or
vildagliptin administered once daily, and
similar to that provided by vildagliptin
administered twice daily.
Keywords: Dipeptidyl peptidase-4; Enzyme
inhibition; Saxagliptin; Sitagliptin; Type 2
diabetes; Vildagliptin
INTRODUCTION
Dipeptidyl peptidase-4 (DPP-4) inhibitors
improve glycemic control in patients with type
2 diabetes mellitus (T2DM) by increasing
circulating levels of incretins, endogenous gut-
derived peptide hormones that enhance insulin
secretion and suppress glucagon release in a
glucose-dependent manner [1–4]. Several DPP-4
inhibitors are widely approved for use as oral
antihyperglycemic agents in treating patients
with T2DM. All have been shown to provide
significant improvements in standard indices of
glycemic control [5]. There may be important
differences between them, however, in the
extent to which they provide sustained
pharmacodynamic (PD) action (DPP-4
inhibition) throughout their recommended
dosing cycles. The existing PD data on these
agents have come from separate studies in
which each agent was evaluated individually,
with different study populations and dosing
regimens (single versus multiple dose
administration) [6–11]. There is a need,
therefore, for comparison of levels of DPP-4
inhibition between different agents within a
single study in which conditions are
standardized. There also is a need to minimize
the impact of dilution and substrate
competition artifacts that may be introduced
in the process of assaying DPP-4 inhibition
ex vivo [9, 11–14] and prevent meaningful
comparison between agents even when tested
in parallel within the same study.
Reagent solutions must be added to plasma
in order to assay DPP-4 activity. As a result,
plasma drug concentrations will be lower in an
ex vivo assay than they are in vivo and this
dilution effect may lead to underestimation of
levels of DPP-4 inhibition. The impact of this
effect will vary depending on the rate at which a
DPP-4 inhibitor dissociates from its binding site
on the enzyme, the amount of plasma dilution,
and the length of time between the addition of
reagents and the measurement of enzyme
activity. In addition, there is the potential for
ex vivo underestimation of DPP-4 inhibition
due to substrate competition. If inhibition is
assessed with substrate present at a level that
saturates the enzyme, then competitive DPP-4
inhibitors are likely to appear to be less effective
than they are under physiological conditions
in vivo, where endogenous substrates are likely
to be present at subsaturating concentrations.
Measurement of DPP-4 inhibition by
sitagliptin is expected to be especially sensitive
to these two artifacts because binding between
sitagliptin and DPP-4 is competitive and rapidly
reversible. When plasma containing sitagliptin is
diluted, the half-life (t1/2) for readjustment to the
new equilibrium for DPP-4 binding is \2 min
[14], an interval that is brief compared with the
length of time over which assays of plasma DPP-4
are typically run. Measurements of DPP-4
inhibition by vildagliptin may also be sensitive
to the dilution artifact because the t1/2 for
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dissociation of vildagliptin from DPP-4 is in the
order of 3.5 min [14]. Measurements of DPP-4
inhibition by saxagliptin and an active
metabolite, 5-hydroxy-saxagliptin, are likely to
be relatively insensitive to this dilution effect
because these molecular species dissociate slowly
from DPP-4, with t1/2 values of 50 and 23 min,
respectively [14]. Given these differences in
binding kinetics, it follows that valid
comparisons between these agents can only be
made when DPP-4 inhibition is measured using
an assay condition that minimizes the impact of
plasma dilution. In the present study, we have
directly compared profiles of DPP-4 inhibition
over time in patients with T2DM treated with
saxagliptin, sitagliptin, and vildagliptin using an
assay in which plasma was diluted by only 11%, a
level that is likely to have only a minimal effect
on outcome, regardless of binding kinetics.
Using a randomized, placebo-controlled, open-
label, crossover design, patients in a single cohort
were treated in successive study periods for
5 days (so that all agents could reach steady-
state conditions) with the highest recommended
doses for each agent. Pharmacokinetic (PK) and
DPP-4 inhibition data were obtained at various
times throughout these treatments and for an
additional 4 days after the last doses were given.
The prespecified primary endpoint was the
‘trough’ level of DPP-4 inhibition measured
after patients received their final doses in each
study period. It was assessed at 24 h postdose in
subjects being treated with study drugs q.d. and
at 12 h postdose in one study period in which
patients were treated b.i.d. (with vildagliptin).
METHODS
This study was performed in accordance with all
local laws and regulations, the Declaration of
Helsinki of 1975, as revised in 2000, and
guidelines established by the International
Conference on Harmonization Good Clinical
Practice. The protocol was approved by the
National Ethics Committee Clinical Research of
Medicines and New Methods of Treatment
(Chisinau, Moldova). Prior to participating, all
patients provided written informed consent.
The study was performed at the Clinical
Republican Hospital (Chisinau, Moldova)
between June and December, 2012.
Patients
Eligible patients were male or female,
18–65 years of age, and had T2DM with HbA1C
values C6.5% and B10.0% either while
treatment-naı¨ve or following washout of prior
oral antihyperglycemic medications for
C6 weeks (12 weeks for patients previously
treated with peroxisome proliferator-activated
receptor-c agonists, insulin, DPP-4 inhibitors, or
glucagon-like peptide-1 analogs). Patients with
fasting plasma glucose[200 mg/dL (11.1 mmol/L)
or estimated creatinine clearance B60 mL/min
were excluded. Concomitant, stable use of
medications for pre-existing hypertension and
dyslipidemia was permitted. Use of medications,
nutritional supplements, and dietary products
known to be cytochrome P3A4/5 (CYP3A4/5)
inhibitors, CYP3A4/5 inducers, P-glycoprotein-1
inhibitors, or human organic anion transporter
3 inhibitors was prohibited.
Study Design
This was an open-label, placebo-controlled, five-
period crossover study in which each patient
received in separate periods 5 mg saxagliptin
q.d., 100 mg sitagliptin q.d., 50 mg vildagliptin
q.d., 50 mg vildagliptin b.i.d. (50 mg every
12 h), and placebo q.d. These specific doses
were tested because each is a highest
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recommended dose. With vildagliptin, 50 mg
b.i.d. is a highest dose approved for use as
monotherapy and 50 mg q.d. is the
recommended dose approved for use in
combination with a sulfonylurea. Assignment
to treatment sequences was randomized using a
computer-generated schedule. Treatments were
administered for 5 days and separated by
C10 days.
Procedures
Patients received nutritional and exercise
counseling and were provided with glucose
meters for home blood glucose monitoring.
They were instructed to perform fingerstick
glucose measurements 5 min before and 2 h
after each meal, and to contact the study-site
staff in the event that any blood glucose value
was \70 mg/dL (3.9 mmol/L) or any fasting
blood glucose value was [200 mg/dL
(11.1 mmol/L). It was prespecified that
patients would be discontinued from the study
in the event of having more than one
occurrence of fasting blood glucose [200 mg/
dL or a single occurrence of any blood glucose
measurement [250 mg/dL (14 mmol/L).
Patients were domiciled in the clinic in each
study period from Day -1 (the day before the
first dose) through the morning of Day 1. They
were also domiciled from the evening of Day 4
through the morning of Day 6 (and provided
with standard meals and snacks during this
time). Approximately 14 days after receiving
final doses of study drug, patients returned for
a follow-up visit. All doses were administered in
the clinic, either during outpatient visits or
while patients were domiciled. The first dose
was preceded by an overnight fast of at least 8 h
and study medications were administered with
approximately 240 mL of water. Evening doses
of vildagliptin were given without regard to
timing of consumption of food or drink.
Blood samples for PD analysis were collected
into VacutainerTM EDTA tubes (Becton
Dickinson, Franklin Lakes, NJ, USA) predose
on Days 1–5 and 12, 24, 36, 48, 96 h after the
final morning dose on Day 5. Plasma was then
isolated by centrifugation, divided into
aliquots, and stored at -80 C until analysis.
Blood samples for PK analysis were collected
predose on Days 1–5 and 0.5, 1, 2, 4, 8, 12, 16,
24, 36, 48, and 96 h following the final morning
dose on Day 5. During treatment with
vildagliptin b.i.d., additional samples were
collected 13 and 14 h after the final morning
dose on Day 5. For analysis of saxagliptin,
5-hydroxy-saxagliptin, and sitagliptin
concentrations, samples were collected into
VacutainerTM K2EDTA tubes (Becton
Dickinson) and plasma was stored at -20 C.
For analysis of vildagliptin, samples were
collected into VacutainerTM P800 tubes
(Becton Dickinson) and plasma was stored at
-80 C.
Measurement of Plasma DPP-4 Activity
Assay of plasma DPP-4 activity was performed at
PPD Bioanalytical Lab (Richmond, VA, USA). In
this assay, 90 lL of plasma was combined with
10 lL of 100 lM glycyl-prolyl-amino-
methylcoumarin hydrobromide (Bachem,
Torrance, CA, USA). The final concentration of
substrate was therefore 10 lM, a level much
lower than the KM of human DPP-4 for this
substrate (approximately 50 lM). Inhibition of
DPP-4 was thus assayed under conditions
designed to minimize the effects of plasma
dilution and substrate competition.
The assay solutions were incubated at 37 C
in a black Immuno Plate (Part # 7205, Thermo
434 Diabetes Ther (2013) 4:431–442
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Scientific, Waltham, MA, USA) on a SpectraMax
Gemini EMTM Fluorescence Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA). Data
were analyzed using SoftmaxPro applications
(Molecular Devices, Sunnyvale, CA, USA).
Formation of reaction product was monitored
by measuring the increase in relative
fluorescence at 460 nm at 45-s intervals (using
360 nm as the excitation wavelength). Enzyme
activity (A) was defined as the slope of this
increase [in relative fluorescent units per
seconds (RFU/s)] measured over the first 5 min
of incubation. In a preliminary analysis, it was
determined that 1 RFU/s was equivalent to
product formation at a rate of approximately
0.2 pmol/s.
Percent inhibition of DPP-4 was calculated as
100 9 (1 - At/A0), where A0 was the enzyme
activity measured predose and At was the
activity measured postdose at time t in the
same treatment period. The lower limit of
quantification (LOQ) for measurement of
A was defined as the lowest level at which the
imprecision (coefficient of variation) of
measurements remained \20%. The LOQ was
regarded as constant across all subjects and
study periods. When At did not exceed the LOQ,
it was assigned the value of the LOQ (0.366
RFU/s).
Pharmacokinetic Analyses
Plasma concentrations of saxagliptin,
5-hydroxy-saxagliptin, sitagliptin, and
vildagliptin were analyzed by liquid
chromatography–tandem mass spectrometry at
Pharmanet Canada, Inc. (now Inventive Health
Clinical, Que´bec City, Que´bec, Canada). The
analysis of sitagliptin was performed as
previously described [15]. For saxagliptin
and 5-hydroxy-saxagliptin, the validated
calibration ranges were 100–50,000 pg/mL and
200–100,000 pg/mL, respectively. For
sitagliptin, the validated range was
1.00–1,000 ng/mL. For vildagliptin, it was
1.00–2,000 ng/mL.
Non-compartmental PK analysis was
performed with actual sampling times using
the WinNonlinTM program (Professional,
version 5.0.1; Pharsight, Mountain View, CA,
USA). Areas under the curve (AUCs) for
concentration versus time were calculated
using the linear trapezoidal method for
ascending concentrations and the log
trapezoidal method for descending
concentrations. The terminal elimination rate
constant (kz) was calculated as the negative of
the slope of the terminal phase of the log-linear
concentration versus time curve. These analyses
included at least three terminal points.
Apparent terminal t1/2 was calculated as
ln(2)/kz.
Statistical Methods
All available data were included in the analysis
(including data from patients who did not
complete the study but had at least one
measurement). Levels of DPP-4 inhibition were
analyzed using a linear mixed-effects model
with fixed-effects terms for treatment and
period. Data were transformed to a log-percent
scale for analysis and then back-transformed to
a linear scale for reporting. Baseline was defined
in each period as the predose value on Day 1.
Inference testing was one-sided and significance
was defined as p\0.05.
A heterogeneous compound symmetry
covariance matrix was used to allow for
unequal treatment variances and to model
correlation between different treatment effects
within the same subject via the REPEATED
Statement in SAS PROC MIXED (SAS
Institute, Inc., Cary, NC, USA). Kenward and
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Roger’s method [16] was used to calculate the
denominator degrees of freedom for the fixed
effects. It was assumed that time and carryover
effects were negligible. One-sided 95%
confidence intervals (CIs) for between-
treatment differences in trough DPP-4
inhibition were calculated using the linear
mixed-effects model mentioned above.
The primary hypothesis was that treatment
of patients with T2DM with 100 mg sitagliptin
q.d. provides significantly greater trough DPP-4
inhibition than treatment with 5 mg
saxagliptin or 50 mg vildagliptin q.d. It was
prespecified that if the lower bound of the one-
sided 95% CI for the difference in trough DPP-4
inhibition between sitagliptin treatment and a
comparator was[0, then this hypothesis would
be confirmed. In addition, 95% CIs were
calculated for the differences between all other
pairs of treatments in this study and summary
statistics were calculated for each treatment and
timepoint in the study.
Based on historical observations of
variability, it was calculated that a sample
comprising 15 completing patients would
provide at least 83% power (a = 0.05, one-
sided) to detect a 20% difference (absolute
percentage points) between treatments in
trough DPP-4 inhibition.
RESULTS
The randomized cohort included 12 women
and 10 men (all Caucasian) with a mean (range)
age of 55 (43–64) years and body mass index of
32 (26–39) kg/m2. Mean (range) baseline HbA1C
was 7.4% (6.4–9.0%).
Five patients discontinued prior to study
completion. One withdrew consent, one was
determined after randomization not to have
met eligibility criteria, and three patients had
elevated blood glucose concentrations that met
the prespecified criteria for discontinuation.
These incidents of elevated blood glucose
occurred primarily prior to dosing with active
treatments (i.e., during washout periods). The
investigator did not consider these to be adverse
events (AEs).
Predose levels of DPP-4 activity (A0) were
3.70–6.36 RFU/s (10.1- to 17.4-fold greater than
the LOQ). Thus, the upper limits for
quantitation of DPP-4 inhibition in individual
measurements were between 90% and 94%.
Actual values varied for each subject and
treatment period based on the baseline DPP-4
activity measured in that period.
Plasma DPP-4 Inhibition
Trough levels of DPP-4 inhibition were
generally stable by the morning of Day 3
during all active treatments (Fig. 1a) and each
of these provided nearly maximal inhibition of
DPP-4 at 12 h postdose as assessed on Day 5
(Fig. 1b). Two of the treatments, sitagliptin and
vildagliptin b.i.d., provided nearly maximal
inhibition at 24 h postdose as determined
predose on Days 1–5 and also on the morning
of Day 6, when the primary endpoint was
assessed. With these treatments, LS-mean
trough DPP-4 inhibition on Day 6 was 91.7%
and 90.6%, respectively (Table 1). The
difference between them was not significant
(p = 0.128).
Treatment with either saxagliptin or
vildagliptin q.d. provided significantly
(p\0.001) less trough DPP-4 inhibition than
treatment with either sitagliptin or vildagliptin
b.i.d. With saxagliptin, the LS-mean trough
DPP-4 inhibition on Day 6 was 73.5% (18.2%
and 17.1% less than with sitagliptin and
vildagliptin b.i.d., respectively). With
vildagliptin q.d., it was 28.9% (62.9% and
61.8% less than with sitagliptin and
436 Diabetes Ther (2013) 4:431–442
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vildagliptin b.i.d., respectively). Treatment with
saxagliptin resulted in 44.6% greater trough
DPP-4 inhibition on Day 6 than treatment with
vildagliptin q.d. (p\0.001).
At 36 and 48 h after morning doses were
given on Day 5, the mean levels of DPP-4
inhibition following sitagliptin treatment were
83% and 72%, respectively (Fig. 1b). Following
vildagliptin b.i.d., saxagliptin, and vildagliptin
q.d., the mean levels of DPP-4 inhibition at
these times were 50% and 17%, 41% and 29%,
and 7% and 21%, respectively. At the final
timepoint (96 h after the morning dose on Day
5), mean DPP-4 inhibition was \25% with all
treatments.
Pharmacokinetic Observations
Observed values for AUC0–24 h, maximal
concentration (Cmax), concentration at 24 h
(C24 h), and other PK parameters are shown in
Table 2. All dosing regimens appeared to result
in steady-state plasma concentrations of parent
drugs by Day 3 (data not shown). Plasma
concentrations of 5-hydroxy-saxagliptin
appeared to reach steady state by Day 5.
Safety
The study treatments were generally well
tolerated. In total, 10 AEs were reported in 7 of
the 22 patients enrolled. Headache was the most
commonly reported AE (six events reported in
three patients). Five AEs were considered to be
study related. These included four events of
headache (two that were attributed to saxagliptin
treatment and two that were attributed to
sitagliptin treatment) and one event of influenza
that was attributed to saxagliptin treatment. All
AEs were reported to be mild (n = 6) or moderate
(n = 4) in intensity and transient in nature. There
were no deaths, no serious AEs, and no AEs that led
to withdrawal from the study.
Other Observations
In any period in which a patient was
administered placebo, plasma concentrations of
saxagliptin, 5-hydroxy-saxagliptin, sitagliptin,
Fig. 1 Mean (±standard error) percent dipeptidyl pepti-
dase-4 (DPP-4) inhibition over time in plasma collected
a predose on Days 1–5 of treatment with 5 mg saxagliptin
q.d., 100 mg sitagliptin q.d., 50 mg vildagliptin q.d., 50 mg
vildagliptin b.i.d., and placebo, and b at the indicated times
on Days 5–9. The measurement at 12 h postdose on Day 5
was obtained before the second vildagliptin b.i.d. dose was
administered. The dashed horizontal lines indicate 94%
inhibition, the maximum level of DPP-4 inhibition that
was quantiﬁable under the assay conditions used in this
study. SE standard error
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and vildagliptin were measured predose on Day
1 and these were observed to be below the LOQ
in all cases. These findings suggest that there was
no carryover of drug concentration from one
period to the next. Similarly, predose levels of
DPP-4 inhibition on Day 1 were similar among
patients in all treatment sequences suggesting no
PD carryover, a conclusion that was further
supported by the results of a sensitivity analysis
in which predose measurements of DPP-4
activity in Period 1, Day 1 were used as the
baseline for all subsequent periods (data not
shown).
DISCUSSION
The findings from this study show that
saxagliptin, sitagliptin, and vildagliptin differ
significantly in the trough levels of DPP-4
inhibition that they provide when
administered to patients with T2DM following
recommended q.d. and b.i.d. dosing regimens.
Sitagliptin and twice-daily vildagliptin each
provided trough inhibition levels of
approximately 90%, the maximum inhibition
level that was observed at any time in this
study. In contrast, saxagliptin and once-daily
Table 1 Percent inhibition of dipeptidyl peptidase-4 activity 24 h after ﬁnal morning doses in patients with type 2 diabetes




Saxagliptin q.d. 20 73.5 (66.6, 79.0)
Sitagliptin q.d. 17 91.7 (91.4, 92.1)
Vildagliptin q.d. 18 28.9 (17.9, 38.4)
Vildagliptin b.i.d. 17 90.6 (88.9, 92.1)
Placebo 17 3.5 (-0.7, 7.5)
Comparison Difference (90% CI)b p value
Sitagliptin q.d. vs. saxagliptin q.d. 18.2 (15.0, 21.7) \0.001
Sitagliptin q.d. vs. vildagliptin q.d. 62.9 (58.2, 67.7) \0.001
Sitagliptin q.d. vs. vildagliptin b.i.d. 1.1 (-0.1, 2.3) 0.128
Sitagliptin q.d. vs. placebo 88.2 (85.8, 90.8) \0.001
Saxagliptin q.d. vs. vildagliptin q.d. 44.6 (34.5, 55.2) \0.001
Saxagliptin q.d. vs. vildagliptin b.i.d. -17.1 (-21.2, -13.3) \0.001
Saxagliptin q.d. vs. placebo 70.0 (58.5, 82.2) \0.001
Vildagliptin q.d. vs. vildagliptin b.i.d. -61.8 (-68.8, -55.2) \0.001
Vildagliptin q.d. vs. placebo 25.4 (15.4, 35.5) \0.001
Vildagliptin b.i.d. vs. placebo 87.1 (80.1, 94.6) \0.001
CI conﬁdence interval
a Back-transformed from a log scale
b Between-treatment differences in percent inhibition; positive values favor the ﬁrst treatment listed at left
438 Diabetes Ther (2013) 4:431–442
123
vildagliptin provided trough inhibition levels of
approximately 75% and 30%, respectively.
Thus, it was observed that sitagliptin and
twice-daily vildagliptin provided sustained,
high levels of DPP-4 inhibition throughout
24 h, whereas saxagliptin and once-daily
vildagliptin did not.
The trough level of DPP-4 inhibition
observed in this study following saxagliptin
treatment corresponded well with the trough
level of inhibition (*70%) observed previously
in a 2-week study in which patients were treated
with saxagliptin 5 mg q.d. [17]. To our
knowledge, there are no published DPP-4
inhibition data from patients treated with
multiple doses of 50 mg vildagliptin b.i.d.;
direct comparison between present and
historical data is thus not possible. In a study
in which single doses of 50 and 100 mg
vildagliptin were given to patients with T2DM,
the levels of DPP-4 inhibition observed at 24 h
postdose were approximately 14% and 35%,
respectively [7]. In the present study, the mean
(±standard error) level of DPP-4 inhibition 24 h
after the first dose of vildagliptin 50 mg q.d. was
9.1 ± 5.0% (Fig. 1). This value is reasonably
consistent with the prior result.
In the present study, sitagliptin provided a
greater trough level of DPP-4 inhibition than
was previously observed in a Phase I trial in
which patients with T2DM were administered a
single dose of 200 mg sitagliptin. In that study,
plasma samples were diluted 2.5-fold prior to
ex vivo assay and the level of DPP-4 inhibition
measured at 24 h postdose was 80.1% [6]. The
greater level of DPP-4 inhibition observed in the
present study could be accounted for by the
difference in plasma dilution. A statistical
method has been described to correct for this
dilution, and based on this method one would
expect to observe 80% DPP-4 inhibition by
sitagliptin after 2.5-fold dilution of plasma
when the true level of inhibition in vivo is
*96% [9]. We have not applied this correction
in the present analysis because the extent of
plasma dilution in our assay was sufficiently
small (11%) that its effect could reasonably be
regarded as negligible.
The PK findings in the present study were
generally consistent with those reported
Table 2 Plasma pharmacokinetic parameters for saxagliptin, 5-hydroxy-saxagliptin (5-OH-saxagliptin), sitagliptin, and
vildagliptin following treatment for 5 days with saxagliptin 5 mg q.d., sitagliptin 100 mg q.d., vildagliptin 50 mg q.d., and













Saxagliptin 20 88.8 (25.2) 1 (0.5–2) 1.1 (41.8) 9.49 (23.9) 341 (24.4) 370 (25.0)
5-OH-Saxagliptin 20 113 (35.1) 2 (1–4) 4.7 (27.8) 14.7 (10.9) 674 (31.7) 784 (31.7)
Sitagliptin 20 724 (31.3) 4 (0.5–8) 84.4 (36.3) 12.0 (31.4) 5,340 (24.9) 7,070 (25.1)
Vildagliptin q.d. 18 586 (37.0) 1 (0.5–8) \LOQc 2.42 (58.5) 2,990 (27.2) 3,100 (27.0)
Vildagliptin b.i.d. 18 759 (34.7) 1 (0.5–4) 7.8 (105.1)d 3.41 (42.2) 3,720 (28.9)e 6,600 (26.3)
a Except where indicated, the data are geometric means (% coefﬁcient of variation)
b Median (range)
c [50% of samples were below the limit of quantitation
d Some samples were below the limit of quantitation; the arithmetic mean (% coefﬁcient of variation) is reported
e N = 17
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previously [6, 8, 10]. It was confirmed that all
plasma drug concentrations were at steady state
when the primary endpoint was measured and
that PD effects were stable from Day 3 onwards.
Hence, differences in drug exposure did not
appear to play a role in the observed differences
in PD effect.
One limitation of this study was that
antihyperglycemic efficacy was not evaluated.
Hence, uncertainty remains as to whether the
observed differences in DPP-4 inhibition have
meaningful implications for glycemic efficacy.
However, a recent, model-based meta-analysis of
published data found evidence for greater
reductions in HbA1C with more sustained DPP-
4 inhibition [18]. Increasing reductions in
HbA1C were found in this meta-analysis even
as the weighted average DPP-4 inhibition
increased beyond 90%, supporting the concept
that maintaining nearly complete inhibition
of DPP-4 over entire dosing cycles may
be important in order to maximize
antihyperglycemic efficacy with this class of
drugs. In addition, we note that the finding of
similar DPP-4 inhibition during treatment in our
comparison of once-daily sitagliptin with twice-
daily vildagliptin is consistent with prior reports
suggesting generally similar glycemic efficacy
when these regimens are compared [19].
In a study comparing the efficacy of sitagliptin
100 mg q.d. with saxagliptin 5 mg q.d. as an add-
on to metformin for 18 weeks, the adjusted mean
change from baseline in HbA1C was -0.62%
versus -0.52% for sitagliptin and saxagliptin,
respectively [20]. Although this difference was
within the study’s prespecified limit for
noninferiority for HbA1C, the sitagliptin group
had a numerically greater adjusted mean change
from baseline in fasting plasma glucose than the
saxagliptin group [-16.2 mg/dL (-0.90 mmol/L)
versus -10.8 mg/dL (-0.60 mmol/L),
respectively]. The results of the present study
suggest a possible mechanism for this glycemic
outcome, in that sitagliptin 100 mg provided
significantly greater DPP-4 inhibition at 24 h
postdose than saxagliptin 5 mg.
CONCLUSION
This study found that three approved DPP-4
inhibitors provided significantly different
trough levels of DPP-4 inhibition when
administered to patients with T2DM following
recommended q.d. and b.i.d. dosing regimens.
Maximal inhibition was sustained throughout
24 h in patients treated with sitagliptin 100 mg
once daily and vildagliptin 50 mg twice daily.
Trough DPP-4 inhibition was submaximal in
patients treated with saxagliptin 5 mg and
vildagliptin 50 mg once daily.
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